LDI and LDA use very dilute concentrations of allergens to help control an exaggerated immune response. An exaggerated immune response is felt to be largely responsible for any number of chronic diseases including auto-immune disease such as Rheumatoid Arthritis, Crohn’s disease, Interstitial Cystitis and Multiple Sclerosis as well as the long-term effects of infectious diseases such as chronic Lyme disease, Bartonella and molds. The difference between LDI and LDA is that LDI is used for infections while LDA is used for overactive immune responses to everyday exposures such as foods, chemicals and pollen. Exposure to any number of these agents can cause a person’s immune system to produce an exaggerated response leading to inflammation and a breakdown of body systems.
LDI and LDA are made up of very dilute concentrations of those offending agents along with a substance called beta-glucuronidase. Beta-glucuronidase is an enzyme made in the body that helps to promote the regulation of special immune cells called T regulator cells. T regulator cells help to dampen the over exaggerated response to whatever the offending agent is that was mixed with the enzyme. Very small amounts of enzyme and agent are used in this process and the solution is given either under the tongue orally or as a subcutaneous injection similar to a TB or PPD injection. Your doctor will decide if you should receive an injection or oral dosage.
The key to LDI/LDA is finding the right concentration of agent to be used. After the first dose, there are usually 3 possible outcomes: 1) improvement in symptoms for a short time (days to up to 7 weeks or more), 2) worsening of symptoms for a short time (days to weeks) and then a return to baseline or 3) no change in symptoms. Under scenario #1, the correct dose was given if the symptoms are controlled for up to 7 weeks and therefore subsequent doses will be given every 7 weeks. If the improvement was a short time (like only a few weeks or less), then the patient will likely need to be given a booster dose of an even more dilute concentration. Under scenario #2, it is likely that the concentration was incorrect and the dilution of the agent needs to be reduced. Under scenario #3, more doses may be needed every 7 weeks before the patient will see improvement. Occasionally 2-3 doses must be given every 7 weeks before the patient will start to see improvement.


Risks for this treatment are extremely low. There is a possibility that symptoms might worsen for a short period of time (days to weeks) or possible hive or swelling over the area where an injection is given.


  • Fibromyalgia
  • Chronic Fatigue Syndrome
  • Lyme Disease
  • Multiple Sclerosis
  • Autoimmune Arthritis
  • Crohn’s Disease
  • Ulcerative Colitis
  • Endometriosis
  • Sarcoidosis
  • Myositis
  • Psoriasis (some forms)
  • Autism
  • Sarcoidosis
  • Interstitial cystitis
  • and other inflammatory type diseases